Sanofi US News

- U.S. adults report issues with sleep, ability to work and feelings of depression and anxiety -

- Data to be presented today during a late breaking abstract session at the 25th Annual European Academy of Dermatology and Venereology (EADV) Congress -

- Joshua Riff, M.D., Named Chief Executive Officer -

- Adlyxin™ is approved as Lyxumia® in more than 60 countries -

Falkner has joined forces with Regeneron and Sanofi Genzyme in collaboration with leading dermatology organizations to educate Americans about a potentially serious, chronic inflammatory skin disease known as atopic dermatitis.

- Both pivotal studies demonstrated superior reduction in HbA1c versus insulin glargine and versus lixisenatide -

- These data, along with previous Phase 3 studies, will be part of a U.S. regulatory submission for dupilumab, which is on track for Q3 of 2016 -

- FDA decisions on the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide and investigational lixisenatide anticipated in Q3 2016 -

- Collaborations Will Work towards Predicting Medication Adherence -

- FDA decision anticipated in August 2016 -

America's Leading National Consumer Research Survey Ranks ACT Advanced Care #1 in "Oral Care" Category

Study Evaluated Adult Patients with Chronic Sinusitis with Nasal Polyposis who did not Respond to Intranasal Corticosteroids

Six researchers each receive $1.625 million in "Pathway to Stop Diabetes®" awards

New 24 and 32-Packs Designed to Manage Dosage Regimens for both Latent and Active Tuberculosis

- A study conducted with 1,500 Americans in July 2015 examined perceived risks of counterfeit medicines[1] -

- First New Drug Application for a GLP-1 receptor agonist to include CV outcomes data -

- LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone -

- Will work together on new digital technology and tools for diabetes -

- Praluent available early next week to U.S. patients -

- ELIXA is the first event-driven cardiovascular outcomes study to provide data for a GLP-1 receptor agonist -

- Includes study in patients who were inadequate responders to, or intolerant of, TNF-alpha inhibitors -

- Results support resubmission of U.S. New Drug Application in Q3 2015 -

Further education about hypoglycemia and routinely monitoring blood glucose levels is needed

- Primary efficacy endpoints met in two trials of alirocumab administered every four weeks -

Awards will provide funding for innovative diabetes researchers